Cetirizine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Cetirizine: H1 antihistamine → nasal cavity disease
One-Sentence Summary
Cetirizine is an oral H1-receptor antihistamine. The TxGNN model predicts it may be relevant to nasal cavity disease, with a score of 0.9977. No clinical trials are registered for this prediction, and the 5 publications retrieved are indirect (reviews, a traditional-medicine mouse study and a study of a different antihistamine), so the evidence is model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Cetirizine belongs to the H1-receptor antagonist (antihistamine) class. The general literature describes competitive blockade of histamine H1-receptors on nerve endings, smooth muscle and glandular cells as the main way these drugs act in allergic disease.
“Nasal cavity disease” is a broad term. Much of it overlaps with allergic and vasomotor nasal conditions where H1 antagonism is already relevant. This is why the model score is high. However, the retrieved literature is general or indirect. It does not offer distinct evidence that cetirizine benefits a new nasal condition beyond those already covered.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11291777 | 2000 | Review | Allergy | Reviews antiallergic effects of H1-receptor antagonists. Histamine receptor blockade is the primary mechanism, but other antiallergic actions may contribute in allergic rhinitis. |
| 37970776 | 2023 | Review | Vestnik otorinolaringologii | Pathogenesis-based approach to treating inflammatory diseases of the nose and paranasal sinuses, aiming to reduce mucosal swelling and mucus. |
| 35818943 | 2022 | Review | Vestnik otorinolaringologii | Modern H1 antihistamines in patients with allergic rhinitis and comorbid acute respiratory infections. |
| 36116201 | 2022 | Preclinical (mouse) | Phytomedicine | Shufeng Jiedu capsule improved olfactory dysfunction in a mouse model of allergic rhinitis. Not a cetirizine study. |
| 9301130 | 1997 | Preclinical (animal) | Arerugi | Betotastine besilate reduced experimental allergic rhinitis in animals. Cetirizine was used as a comparator and inhibited the response dose-dependently. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 4175R | Alzene | Tablet 10 mg | Not recorded in the local data |
Safety Considerations
Product Information warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Drug Interactions: 100 interactions were recorded. The main moderate-level ones include:
- Bupropion
- Dronabinol
- Loperamide
- Metoclopramide
- Morphine (including liposomal)
- Nabilone
- Opium
- Sibutramine
- Difenoxin
- Diphenoxylate
Several others (e.g. calcitriol, vitamin A, phentermine, pantoprazole, glimepiride) are recorded with an unknown severity level.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone. No cited study directly examines cetirizine in nasal cavity disease, and the broad term largely overlaps with allergic and vasomotor rhinitis, so it adds little distinct new-indication evidence.
To proceed, the following is needed:
- A more specific definition of which nasal condition is targeted, distinct from existing allergic and vasomotor rhinitis
- Clinical studies of cetirizine in that specific condition
- Mechanism of action data
- TGA Product Information warnings and contraindications for safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.